Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 1Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
May 14Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 9Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Jan 8Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Dec 20, 2023Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
Nov 24, 2023Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Jun 28, 2023Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome
Jun 20, 2023Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 15, 2023ANAVEX®2-73 Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 12, 2023Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ
Jun 6, 2023Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
May 2, 2023Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Apr 25, 2023Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Feb 2, 2023Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)
